Subcutaneous amivantamab offers faster treatment, fewer infusion reactions, and improved convenience for patients with EGFR-mutated NSCLC, says Estelamari Rodriguez, MD, MPH.
Estelamari Rodriguez, MD, MPH
Advertisement
Estelamari Rodriguez, MD, MPH, is the associate director of community outreach for thoracic oncology and the assistant director of diversity, equity, & inclusion at the University of Miami Sylvester Comprehensive Cancer Center.
Articles by Estelamari Rodriguez, MD, MPH
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5